Progesterone supplementation for preventing preterm birth: A systematic review and meta-analysis

Acta Obstetricia et Gynecologica Scandinavica

Volumn 84, Issue 6, 2005, Pages 526-533

  Dodd, Jodie M ^a   Crowther, Caroline A ^a   Cincotta, Robert ^b   Flenady, Vicki ^b   Robinson, Jeffrey S ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b Mater Mother's Hospital   (Australia)

Author keywords

Perinatal morbidity and mortality; Preterm birth; Progesterone; Randomized trial; Systematic review

Indexed keywords

CORTICOSTEROID; HYDROXYPROGESTERONE CAPROATE; PLACEBO; PROGESTERONE; UTERUS SPASMOLYTIC AGENT;

BIRTH WEIGHT; BRAIN HEMORRHAGE; BREAST TENDERNESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COUGHING; DRUG EFFICACY; FEMALE; GESTATIONAL AGE; HEADACHE; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; INJECTION SITE REACTION; META ANALYSIS; NAUSEA; NEWBORN MORTALITY; PRACTICE GUIDELINE; PREGNANCY; PREMATURE LABOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVAGINAL; BIRTH WEIGHT; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; OBSTETRIC LABOR, PREMATURE; PREGNANCY; PROGESTERONE; RANDOMIZED CONTROLLED TRIALS; TOCOLYTIC AGENTS;

EID: 19944367886     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0001-6349.2005.00835.x     Document Type: Review

References (46)

1. AIHW. Australia's Mothers and Babies 2000. Sydney: Australian Institute of Health and Welfare National Perinatal Statistics Unit, 2003.
2. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacher F, Munson ML. Births: final data for 2002. Natl Vital Stat Rep 2003; 52: 1-113.
3. Elder DE, Hagan R, Evans SF, Benninger HR, French NP. Hospital admissions in the first year of life in very preterm infants. J Paediatr Child Health 1999; 35: 145-50.
4. Stanley F. Survival and cerebral palsy in low birthweight infants: implications for perinatal care. Paediatr Perinat Epidemiol 1992; 6: 298-310.
5. Challis JR, Matthews SG, Gibb W, Lye SJ. Endocrine and paracrine regulation of birth at term and preterm. Endocr Rev 2000; 21: 514-50.
6. Challis JR, Sloboda DM, Alfaidy N, Lye SJ, Gibb W et al. Prostaglandins and mechanisms of preterm birth. Reproduction 2002; 124: 1-17.
7. Gibb W, Challis JR. Mechanisms of term and preterm birth. J Obstet Gynaecol Can 2002; 24: 874-83.
8. Lopez Bernal A. Mechanisms of labour - biochemical aspects. Br J Obstet Gynaecol 2003; 110: 39-45.
9. Pepe GJ, Albrecht ED. Actions of placental and fetal adrenal steroid hormones in primate pregancy. Endocr Rev 1995; 16: 608-48.
10. Haluska GJ, Cook MJ, Novy MJ. Inhibition and augmentation of progesterone production during pregnancy: effects on parturition in rhesus monkeys. Am J Obstet Gynecol 1997; 176: 682-91.
11. Pieber D, Allport VC, Hills F, Johnson M, Bennett PR. Interactions between progesterone receptor isoforms in myometrial cells in human labour. Mol Hum Reprod 2001; 7: 875-9.
12. Check JH, Lee G, Epstein R, Vetter B. Increased rate of preterm deliveries in untreated women with luteal phase deficiencies. Preliminary report. Gynecol Obstet Invest 1992; 33: 183-4.
13. Rodger MW, Baird DT. Induction of therapeutic abortion in early pregnancy with mifepristone in combination with prostaglandin pessary. Lancet 1987; 2: 1415-8.
14. el-Refaey H, Hinshaw K, Henshaw R, Smith N, Templeton A. Medical management of missed abortion and anembryonic pregnancy. BMJ 1992; 305: 1399.
15. Nyboe-Andersen A, Popovic-Todorovic B, Schmidt KT, Loft A, Lindhard A, Hojgaard A et al. Progesterone supplementation during early gestations after IVF or ICSI has no effect on the delivery rates: a randomized controlled trial. Hum Reprod 2002; 17: 357-61.
16. Grazzini E, Guillon G, Mouillac B, Zingg HH. Inhibition of oxytocin receptor function by direct binding of progesterone. Nature 1998; 392: 509-12.
17. Astle S, Slater DM, Thornton S. The involvement of progesterone in the onset of human labour. Eur J Obstet Gynecol Reprod Biol 2003; 108: 177-81.
18. Jenkin G, Thorburn GD. Inhibition of progesterone secretion by a 3 beta hydroxysteroid dehydrogenase inhibitor in late pregnant sheep. Can J Physiol Pharmacol 1985; 63: 136-42.
19. Block BS, Liggins GC, Creasy RK. Preterm delivery is not predicted by serial plasma estradiol or progesterone concentration measurements. Am J Obstet Gynecol 1984; 150: 716-22.
20. Smit DA, Essed GG, deHaan J. Predictive value of uterine contractility and the serum levels of progesterone and oestrogens with regard to preterm labour. Gynecol Obstet Invest 1984; 18: 252-63.
21. Haluska GJ, Wells TR, Hirst JJ, Brenner RM, Sadowsky DW, Novy MJ. Progesterone receptor localization and isoforms in myometrium, decidua, and fetal membranes from rhesus macaques: evidence for functional progesterone withdrawal at parturition. J Soc Gynecol Investig 2002; 9: 125-36.
22. Condon JC, Jeyasuria P, Faust JM, Wilson JW, Mendelson CR. A decline in the levels of progesterone receptor coactivators in the pregnant uterus at term may antagonize pregesterone receptor function and contribute to the initiation of parturition. Proc Natl Acad Sci U S A 2003; 100: 9518-23.
23. da Fonseca EB, Bittar RE, Carvalho MHB, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol 2003; 188: 419-24.
24. Meis PJ, Klebanoff M, Thom E, Mitchell P. Prevention of recurrent preterm delivery by 17-alpha hydroxyprogesterone caproate. N Engl J Med 2003; 348: 2379-85.
25. LeVine L. Habitual abortion. A controlled clinical study of progestational therapy. West J Surg Obstet Gynecol 1964; 72: 30-6.
26. Papiernik-Berkhauer E. Etude en double aveugle d'un medicament prevenant la survenue prematuree de l'accouchement chez les femmes a risque eleve d'accouchement premature edition. Schering Serie IV 1970; 3: 65-8.
27. Johnson JWC, Austin KL, Jones GS, Davis GH, King TM. Efficacy of 17 alpha hydroxyprogesterone caproate in the prevention of premature labor. N Engl J Med 1975; 293: 675-80.
28. Hauth JC, Gilstrap LC, Brekken AL, Hauth JM. The effect of 17 alpha hydroxyprogesterone caproate on pregnancy outcome in an active-duty military population. Am J Obstet Gynecol 1983; 146: 187-90.
29. Yemini M, Borenstein R, Dreazen E, Apelman Z, Mogilner BM, Kessler I et al. Prevention of premature labor by 17alpha hydroxyprogesterone caproate. Am J Obstet Gynecol 1985; 151: 574-7.
30. Doggrell SA. Recurrent hope for the treatment of preterm delivery. Expert Opin Pharmacother 2003; 4: 2363-6.
31. Greene MF. Progesterone and preterm delivery - deja vu all over again. N Engl J Med 2003; 348: 2453-5.
32. Brancazio LR, Murtha AP, Heine RP. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med 2003; 348: 2379-85.
33. Elovitz M, Wang Z. Medroxyprogesterone acetate, but not progesterone, protects against inflammation-induced parturition and intrauterine fetal demise. Am J Obstet Gynecol 2004; 190: 693-701.
34. Crossley KJ, Nicol MB, Hirst JJ, Walker D, Thorburn GD. Suppression of arousal by progesterone in fetal sheep. Reprod Fertil Dev 1997; 9: 767-73.
35. Nicol MB, Hirst JJ, Walker D, Thorburn GD. Effect of alteration of maternal plasma progesterone concentrations on fetal behavioural state during late gestation. J Endocrinol 1997; 152: 379-86.
36. Nicol MB, Hirst JJ, Walker D. Effects of pregnanolone on behavioural parameters and the responses to GABA (A) receptor antagonists in the late gestation fetal sheep. Neuropharmacology 1999; 38: 49-63.
37. Iams JD. Supplemental progesterone to prevent preterm birth. Am J Obstet Gynecol 2003; 188: 303.
38. American College of Obstetrics and Gynecology Opinion Statement. Use of progesterone to reduce preterm birth. Obstet Gynecol 2003; 102: 1115-6.
39. Abate A, Brigandi A, Costabile L, Abate FG, Balzano E, Perino M. 17-alpha-hydroxyprogesterone caproate and natural progesterone in assisted reproduction: a comparative study. Clin Exp Obstet Gynecol 1997; 24: 190-2.
40. Levy T, Yairi Y, Bar-Hava I, Shalev J, Orvieto R, Ben-Rafael Z. Pharmacokinetics of the progesterone-containing vaginal tablet and its use in assisted reproduction. Steroids 2000; 65: 645-9.
41. Tavaniotou A, Smitz J, Bourgain C, Devroey P. Comparison between different routes of progesterone administration as luteal phase support in infertility treatments. Hum Reprod Update 2000; 6: 139-48.
42. Penzias AS. Luteal phase support. Fertil Steril 2002; 77: 318-23.
43. Cicinelli E, Savino F, Cagnazzo I, Scorcia P. Comparative study of progesterone plasma levels after nasal spray and intramuscular administration of natural progesterone in menopausal women. Gynecol Obstet Invest 1993; 35: 172-4.
44. Mircioio C, Perju A, Neagu A, Griu E, Calin G, Miron DS. Pharmacokinetics of progesterone in postmenopausal women: 1. Pharmacokinetics following intravaginal administration. Eur J Drug Metab Pharmacokinet 1998; 23: 391-6.
45. Levy T, Gurevitch S, Bar-Hava I, Ashkenazi J, Magazanik A, Homburg R et al. Pharmacokinetics of natural progesterone administered in the form of a vaginal tablet. Hum Reprod 1999; 14: 606-10.
46. Onsrud M, Paus E, Haug E, Kjorstad K. Intramuscular administration of hydroxyprogesterone caproate in patients with endometrial carcinoma. Pharmacokinetics and effects on adrenal function. Acta Obstet Gynecol Scand 1985; 64: 519-23.